UBXN7 Antibody [DyLight 350]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-22223UV
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Mouse
Predicted:
Orangutan (100%). Backed by our 100% Guarantee.
Applications
Immunoprecipitation, Western Blot
Label
DyLight 350 (Excitation = 353 nm, Emission = 432 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
The immunogen this antibody was made to, maps to a region between residue 439 and 489 of human UBX domain protein 7 using the numbering given in entry NP_056377.1 (GeneID 26043).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for UBXN7 Antibody [DyLight 350]
Application
Recommended Usage
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: UBXN7
Alternate Names
KIAA0794, UBX domain containing 7, UBX domain protein 7, UBX domain-containing protein 7, UBXD7
Gene Symbol
UBXN7
Additional UBXN7 Products
Product Documents for UBXN7 Antibody [DyLight 350]
Product Specific Notices for UBXN7 Antibody [DyLight 350]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...